Eventzilla

15th Annual Infectious Diseases Update

Friday, Jun 7, 2024 at 9:00 AM to 1:00 PM EDT

1300 York Avenue, New York, New York, 10065, United States

Registration

Access code applied successfully. Remove

Invalid access code. Try again
Have an access code?

Sale ended

In-Person General Admission Partial Approval - $30.00

In-Person General Admission Registration fee to be paid to Weill Cornell Medicine inclusive of: admission to program, course materials and refreshments.

sales ended

Virtual General Admission Partial Approval - $30.00

Virtual attendance via ZOOM registration fee to be paid to Weill Cornell Medicine inclusive of: admission to program and course materials.

Enter your discount code

Subtotal (excluding fees and discounts)
Fee
Total amount

Event Information

Friday, Jun 7, 2024 at 9:00 AM to 1:00 PM EDT

Uris Auditorium, 1300 York Avenue, New York, New York, 10065, United States.

Weill Cornell Medicine - Division of Infectious Diseases is proud to present our 15th Annual Infectious Diseases Update.

This program will provide attendees with information on:

Updates in the Diagnosis and Treatment of Tuberculosis
The Ins and Outs of Next Generation Sequencing in Clinical Microbiology and Infectious Disease
Treatment of Multi-Drug Resistant Pathogens - Strategies and Challenges
What is New in CMV?
Let's talk about DoxyPEP for Prevention of Sexually Transmitted Infections

Target Audience: The conference is intended for primary care providers (internists, family care practitioners) and infectious disease and HIV specialists, including, physicians, nurse practitioners and physician assistants. Anyone who is interested in this program is welcome to attend.

*REGISTRATION FEE: $30 (Free for Residents, Fellows and Medical Students)

*Registration fee to be paid to Weill Cornell Medicine inclusive of: admission to program and course materials (coffee break will be provided for in-person attendees).

Accreditation Statement: Weill Cornell Medical College is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Weill Cornell Medical College designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Upon successful completion of this course, Weill Cornell Medical College will submit your completion data to ABIM via ACCME’s Program and Activity Reporting System (PARS) for MOC points.

Speakers

Learn more aboutMarshall Glesby, MD, PhD

Marshall Glesby, MD, PhD

Professor of Medicine and Population Health Sciences, Associate Chief, Division of Infectious Diseases

Weill Cornell Medicine

Marshall Glesby, MD, PhD is a Professor of Medicine and Population Health Sciences, Director of the Cornell HIV Clinical Trials Unit, Associate Chief of the Division of Infectious Diseases, and Vice Chair for Mentoring and Faculty Development in the Department of Medicine at Weill Cornell Medical College. He is the Regional Clinical Director of the NECA AETC. He is an active investigator in the NIH-sponsored Adult AIDS Clinical Trials Group (ACTG) and Women’s Interagency HIV Study (WIHS). He is an Assistant Editor of the Journal of Acquired Immune Deficiency Syndromes and a former member of the Antiviral Drugs Advisory Committee of the Food and Drug Administration (FDA). Dr. Glesby has co-authored over 150 peer reviewed articles.

Learn more aboutRoy Gulick, MD

Roy Gulick, MD

Rochelle Belfer Professor of Medicine Chief, Division of Infectious Diseases

Weill Cornell Medicine

Dr. Gulick is Rochelle Belfer Professor in Medicine and Chief of the Division of Infectious Diseases at Weill Cornell Medicine and Attending Physician at the New York Presbyterian Hospital in New York City. He is board certified in internal medicine and infectious diseases. Dr. Gulick’s research interests include designing, conducting and analyzing clinical trials to refine antiretroviral therapy strategies for HIV treatment and prevention and assess antiviral agents with new mechanisms of action. He currently serves as Principal Investigator of the Cornell-New Jersey HIV Clinical Trials Unit of the AIDS Clinical Trials Group (ACTG) and the HIV Prevention Trials Network (HPTN), sponsored by the U.S. National Institutes of Health. He also serves as the Co-Chair of the U.S. Department of Health and Human Services (DHHS) Panel on Clinical Practices for Treatment of HIV Infection and as the Co-Chair of the NIH COVID-19 Treatment Guidelines Panel. He previously served as a Member and as Chair of the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) and as a Member and as Chair of the NIH Office of AIDS Research Advisory Committee (OARAC). He is a Member of the American Society of Clinical Investigation (ASCI), the Association of American Physicians (AAP), International AIDS Society (IAS), and the Infectious Diseases Society of America (IDSA), and has presented at national and international meetings and published widely.

Learn more aboutMichael Satlin, MD, MS

Michael Satlin, MD, MS

Associate Professor of Medicine Clinical Director of the Transplantation-Oncology Infectious Diseases Program

Weill Cornell Medicine Division of Infectious Diseases

Dr. Satlin is an infectious diseases physician and Associate Professor of Medicine and Associate Professor of Pathology and Laboratory Medicine at Weill Cornell Medicine. He is the Clinical Director of the Transplantation-Oncology Infectious Diseases Program at Weill Cornell. He completed medical school at the University of Virginia School of Medicine and internal medicine residency and fellowship training at NewYork-Presbyterian Hospital/Weill Cornell. He also obtained a Master’s Degree in Clinical and Translational Investigation at Weill Cornell. His research focuses on the epidemiology, prevention, and treatment of multidrug-resistant Gram-negative infections, with a particular focus on immunocompromised hosts. He has an R01 grant through the National Institute of Allergy and Infectious Diseases (NIAID) to investigate the role of screening for resistant enteric bacteria to personalized infection prevention strategies in neutropenic patients. He is on the Editorial Advisory Boards of Clinical Infectious Diseases and Open Forum Infectious Diseases and Associate Editor for Journal of Antimicrobial Chemotherapy-Antimicrobial Resistance. He has authored or co-authored over 70 peer-reviewed manuscripts. He is a Member of the Clinical and Laboratory Standards Institute’s (CLSI) Subcommittee on Antimicrobial Susceptibility Testing and Co-Chair of its Breakpoint Working Group. Lastly, he serves on the ASM Microbe Program Committee and is a Member of multiple committees for the NIAID’s Antibacterial Resistance Leadership Group.

Learn more aboutYotam Arens, MD

Yotam Arens, MD

Instructor in Medicine

Weill Cornell Medical College Division of Infectious Diseases

Yotam Arens, MD, is an Instructor in the Division of Infectious Diseases at Weill Cornell Medical College. He attends on the General Infectious Disease consult service and is a primary care physician in the Center for Special Studies for people with HIV and at risk of HIV infection. He obtained his medical degree at the Icahn School of Medicine at Mount Sinai and completed his Internal Medicine residency and Infectious Diseases fellowship at the Hospital of the University of Pennsylvania. His clinical research has focused on early-stage anal cancer and precursor lesions among people with HIV, as well as HIV-associated kidney disease and the role of HIV infection on nicotine metabolism among people with HIV. He also participated in the Masters of Science of Clinical Epidemiology at the University of Pennsylvania and is studying the role of sexually transmitted infections in Hepatitis C virus transmission using data from the CNICS cohort.

Learn more aboutEsther Babady, Ph.D., D (ABMM), FIDSA, FAAM

Esther Babady, Ph.D., D (ABMM), FIDSA, FAAM

Chief of Clinical Microbiology Service

Memorial Sloan Kettering Cancer Center Dept. of Pathology & Laboratory Medicine, Dept. of Medicine

Dr. Babady is the Chief of Clinical Microbiology Service, an Attending Microbiologist and Member (Professor) in the Department of Pathology and Laboratory Medicine and the Department of Medicine (Infectious Disease Service) at Memorial Sloan Kettering Cancer Center. She received her doctoral degree in Biochemistry and Molecular Biology and completed a post-doctoral fellowship in Clinical Microbiology both at the Mayo Clinic in Rochester, MN. She serves on several professional societies committees and was recently appointed to the CDC Clinical Laboratory Improvement Advisory Committee (CLIAC). Dr. Babady is a Senior Editor for Microbiology Spectrum and Associate Editor for the Journal of Molecular Diagnostics. She has published extensively on the development, validation and evaluation of molecular methods for infectious diseases diagnostic and their impact on cancer patient outcomes. She is an elected fellow of Infectious Disease Society of America and a fellow of the American Academy of Microbiology.

Learn more aboutAlexander Drelick, MD

Alexander Drelick, MD

Assistant Professor, Medicine

Weill Cornell Medicine

Learn more aboutMelanie Dubois, MD MPH

Melanie Dubois, MD MPH

Assistant Professor of Pediatrics

Weill Cornell Medicine Pediatric Infectious Diseases

Dr. Dubois is an Assistant Professor in Pediatric Infectious Diseases at Weill Cornell Medicine. She trained for medical school at University of Massachusetts, for pediatric residency at Children’s Hospital at Montefiore, and for pediatric infectious disease fellowship at Boston Children’s Hospital. She additionally completed her Master of Public Health at Harvard T.H. Chan School of Public Health. She is a clinician-researcher interested in improving screening, diagnosis, and prevention of tuberculosis in pregnant persons living with HIV, children, and adolescents in Botswana and worldwide.

Learn more aboutKeith Kaye, MD

Keith Kaye, MD

Chief, Division of Allergy, Immunology and Infectious Diseases

Rutgers Robert Wood Johnson Medical School Department of Medicine

Dr. Kaye is the Chief, Division of Allergy, Immunology and Infectious Diseases, and is Professor of Medicine in the Department of Medicine at Rutgers Robert Wood Johnson Medical School. He has devoted his career to the prevention and effective management of healthcare-associated infections. In addition to serving in a variety of quality improvement and administrative roles in infection prevention, antimicrobial stewardship, and quality and patient safety, he has served on national and international clinical guidelines committees. Dr. Kaye’s research interests include prevention and treatment of antimicrobial resistant organisms, prevention of healthcare associated infections, and innovative approaches to antimicrobial stewardship. He has a long and productive track record of federal funding for research pertaining to management of healthcare associated infections (HAIs) and multi-drug resistant organisms (MDROs) including Acinetobacter baumannii, carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa. He has conducted innovative, groundbreaking clinical trials on HAIs and MDROs. Dr. Kaye received his medical degree from the University of Pennsylvania and completed his Internal Medicine residency and Infectious Diseases fellowship at Beth Israel Deaconess Medical Center in Boston, MA. During fellowship, Dr. Kaye earned a Masters in Public Health from the Harvard School of Public Health. Dr. Kaye has published more than 350 peer-reviewed articles e and has authored more than 20 book chapters. He also frequently presents original research at national and international conferences. Dr. Kaye is a past President of the Society for Health Epidemiology of America (SHEA). He is an internationally recognized expert in healthcare epidemiology and antimicrobial resistance and has been invited to speak on these topics at venues throughout the world.

Event Schedule

Welcome
Register
Learning
Programming
Advantages
Workshop
Managemet
Programs
test
- test

09:00 AM